Beer TM - Search Results

1

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Rathkopf DE, et al. Among authors: beer tm. Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6. Eur Urol. 2014. PMID: 24647231 Free PMC article. Clinical Trial.

2

Complications of chemotherapy for prostate cancer.

Beer TM, Bubalo JS. Beer TM, et al. Semin Urol Oncol. 2001 Aug;19(3):222-30. Semin Urol Oncol. 2001. PMID: 11561990 Review.

3

Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.

Hayes-Lattin BM, Kovach PA, Henner WD, Beer TM. Hayes-Lattin BM, et al. Among authors: beer tm. Urology. 2002 Jan;59(1):137. doi: 10.1016/s0090-4295(01)01481-9. Urology. 2002. PMID: 11796304

4

Unilateral autonomous testicular testosterone production mimicking androgen independent prostate cancer.

Lavelle M, Schuff KG, Keller FS, Binkert CA, O'Hara M, Fairfax CA, Beer TM. Lavelle M, et al. Among authors: beer tm. J Urol. 2002 Sep;168(3):1098-9. doi: 10.1016/S0022-5347(05)64586-7. J Urol. 2002. PMID: 12187234 No abstract available.

5

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.

Beer TM, Garzotto M, Eilers KM, Lemmon D. Beer TM, et al. J Urol. 2003 May;169(5):1738-41. doi: 10.1097/01.ju.0000059584.47272.9d. J Urol. 2003. PMID: 12686821 Clinical Trial.

6

Advanced penile carcinoma.

Culkin DJ, Beer TM. Culkin DJ, et al. Among authors: beer tm. J Urol. 2003 Aug;170(2 Pt 1):359-65. doi: 10.1097/01.ju.0000062829.43654.5e. J Urol. 2003. PMID: 12853775 Review.

7

Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Beer TM, et al. Br J Cancer. 2003 Sep 15;89(6):968-70. doi: 10.1038/sj.bjc.6601232. Br J Cancer. 2003. PMID: 12966410 Free PMC article. Clinical Trial.

8

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.

Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Beer TM, et al. Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045. Urology. 2004. PMID: 14972486

9

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Beer TM, et al. Clin Cancer Res. 2004 Feb 15;10(4):1306-11. doi: 10.1158/1078-0432.ccr-1021-03. Clin Cancer Res. 2004. PMID: 14977829 Clinical Trial.

10

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.

Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Tiffany NM, et al. Among authors: beer tm. Urology. 2004 May;63(5):934-9. doi: 10.1016/j.urology.2003.12.022. Urology. 2004. PMID: 15134984 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

300 results

Search Page